Leukemia stem cell test for AML relapse in children
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML).
- You must be 18 years old or younger.
- You must be able to understand and sign a consent form.
- You should not have severe heart, liver, or kidney problems.
- You should not have a severe infection.
- You should not have other health issues that would prevent chemotherapy or a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This trial tests a new cell therapy (BG1805) for children whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The therapy targets a specific marker on leukemia cells called CLL-1 and aims to help the immune system fight the cancer.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.